Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC12267 + methotrexate
- Development stage
- Unknown
- Lead developer
- 4SC
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SC12267 + methotrexate is a **combination therapy** involving SC12267 (also known as 4SC-101) and methotrexate, evaluated for use in **rheumatoid arthritis**. SC12267 is an experimental disease-modifying antirheumatic drug (DMARD); methotrexate is an established antimetabolite and immunosuppressant used in rheumatoid arthritis and various cancers[1][6]. The combination aims to improve efficacy in reducing inflammation and preventing joint damage by combining the mechanisms of a novel DMARD (SC12267) with the anti-inflammatory and antiproliferative effects of methotrexate. The trial for this combination was sponsored by 4SC AG[1]. Details on the exact mechanism of SC12267 are limited in public databases, but as a novel DMARD, it likely targets immune pathways involved in rheumatoid arthritis pathology, while methotrexate inhibits dihydrofolate reductase and interferes with DNA synthesis and immune cell function[6].
- Other names
- SC12267 + methotrexate4SC-101 + methotrexate
02
Targets
DHFR (Dihydrofolate reductase)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)
Beyond the preview
Go deeper on SC12267 + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC12267 + methotrexate.